Clinical Trial Update: Effect of Procrit (Epoetin Alfa) on Preventing Delayed Graft Function After Deceased Donor Renal Transplantation [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial evaluated whether Procrit (epoetin alfa) can prevent delayed graft function after deceased donor kidney transplantation; the study has …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Delayed Graft Function

Drugs mentioned

• PROCRIT (ERYTHROPOIETIN)

Snippet

Sponsor: West Penn Allegheny Health System | Conditions: Delayed Graft Function | Phase 4 | Status: COMPLETED